PHILADELPHIA, March 24, 2015 /PRNewswire/ -- ACI Clinicalannounces a new solution for Life Sciences companies facing the growing difficulty surrounding the identification and engagement of independent medical experts. With over a decade of experience building and managing a global network of medical thought leaders, ACI offers a complete solution that simplifies all aspects of the recruitment, contracting and payment process. With pressure from new regulations like the Sunshine Payments Act, clients can contact ACI today to find the expertise needed for everything from study design to clinical consulting to full service Endpoint Adjudication and Data Monitoring Committee solutions.
Common challenges in Engaging Medical Experts
Medical experts are frequently contracted by pharmaceutical, biotech and device companies to provide thought leadership expertise at various points of development and post-marketing. Experts often serve as consultants for study design and safety issues, or as members of independent data review committees.
Finding the right match for unique project needs while complying with regulations around Health Care Provider (HCP) transfers of value can bring many challenges that ACI Clinical can help to solve:
Assistance with Fair Market Value (FMV) Determinations
Although various mechanisms are in place to establish HCP value, such as MGMA reports, these rates often don't reflect the added-value of leading medical experts. Thought-leader expertise is so rare that there is no readily available published source of fair market rates for these individuals. Given ACI's long history of managing independent expert committees – from identification and vetting to negotiating rates and managing payments – ACI holds unique insight into the actual data. Clients looking for medical expert FMV payment information can turn to ACI for real-world contractual data on hourly rates of experts in over 20 countries.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.